

(19)



(11)

**EP 2 856 934 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**08.04.2015 Bulletin 2015/15**

(51) Int Cl.:

**A61B 5/00 (2006.01)**

**A61B 5/055 (2006.01)**

(21) Application number: **13290238.8**

(22) Date of filing: **04.10.2013**

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

(71) Applicant: **Les Laboratoires Servier**

**92284 Suresnes Cedex (FR)**

(72) Inventors:

• **Jabourian, Maritza**

**75018 Paris (FR)**

• **Fossati, Philippe**

**78480 Verneuil SUR Seine (FR)**

• **Delaveau, Pauline**

**75012 Paris (FR)**

(74) Representative: **Bestel, Delphine**

**BIOREALITES**

**Direction Brevets**

**35 rue de Verdun**

**92284 Suresnes Cedex (FR)**

(54) **Biomarkers for the prediction of long term remission in depression**

(57) Methods for predicting long-term remission among depressed patients. Biomarkers for the prediction of long-term remission in depression.

**EP 2 856 934 A1**

## Description

**[0001]** The present disclosure relates to methods for predicting long-term remission among depressed patients. In certain embodiments, the invention relates to identify brain regions whose pre-treatment activity could predict the long-term remission of depressed patients with depressant treatment, such as agomelatine.

**[0002]** Two third of patients treated for major depressive disorder (MDD) show a response (symptom reduction >50 %) to an initial antidepressant treatment. However, with a first-line treatment, fewer than 30 % of depressed patients achieved clinical remission, defined as a score of Hamilton Rating Scale for Depression (HAM-D) of 7 or less. Ineffective treatment of depression increases the medical and economic burden of the disorder, puts the patients at risk of suicide and might contribute to the development of treatment-resistant depression and long-term higher relapse rate. Overall this calls for the development of biomarkers that may help the clinician to predict long-term treatment outcome.

**[0003]** Biological predictors such as pre-treatment regional brain activity measured by positron emission tomography (PET) or quantitative activity measured by electroencephalography emerge from brain imaging research. Increased pre-treatment resting rostral anterior cingulate cortex (rACC) activity or reduced ability to suppress rACC activation during cognitive tasks have been proposed as markers of treatment response to antidepressant, electroconvulsive therapy or repetitive transcranial magnetic stimulation in depression. However such predictors have not been adopted in clinical setting due to the relative lack of reliability and validity of these measures. Moreover, up to now, the identified brain imaging markers have been showed to predict clinical response but not clinical remission, which is the primary goal of the treatment.

**[0004]** The main goal of the present study was to use functional magnetic resonance imaging fMRI to identify brain regions whose activity during self-referential processing could predict the long-term remission of MDD patients treated with antidepressant such as agomelatine, an agonist of MT1-MT2 melatonergic receptors and an antagonist of the serotonergic 5-HT<sub>2C</sub> receptor. To control for learning effect due to the repetition of the self-referential task and assess potential normalization of cerebral activity, we included healthy volunteers receiving placebo for one week. Increased self-focus, the tendency to excessively engage in self-referential processing, is a core feature of acute depression and is associated with abnormal activity of dorsomedial and dorsolateral prefrontal cortex, key regions in the pathophysiology of MDD (7-8). Here we assessed depressed patients making self-referential judgments on emotional pictures during two fMRI acquisitions: 1) before treatment when patients were acutely depressed and 2) following 6 to 7 weeks of treatment with Agomelatine. We hypothesized first that the activity of brain regions associated with self-referen-

tial processing at inception would be predictive of clinical remission six months later on.

**[0005]** There is a need in the art for a useful approach to assess a depressed patient, to predict long-term remission in patients with depression and to provide markers for evaluating said prediction of remission.

**[0006]** The present invention provides a method of predicting remission in patients with depression wherein a pre-treatment level of activation in cortical midline regions (CMR) identify patients achieving remission after antidepressant treatment.

**[0007]** "Remission" or "long-term remission" can be defined as a complete or near complete absence of symptoms. There is now a consensus among experts to suggest that achieving long-term remission is the primary goal in the treatment of depression. Patients achieving remission have a lower likelihood of depressive recurrence and a better psychosocial functioning compared to patients with residual depressive symptoms.

**[0008]** By "depression" is meant Major Depressive Episode (MDE) consisting in:

- Major Depressive Disorder (MDD) comprising clinical depression, major depression, unipolar depression, unipolar disorder or as recurrent depression in the case of repeated episodes, is a mental disorder characterized by a pervasive and persistent low mood which is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities;
- Bipolar Disorder comprising bipolar affective disorder, manic-depressive disorder or manic depression, is a mental illness classified by psychiatry as a mood disorder. Individuals with bipolar disorder experience episodes of a very high mood known as mania alternating with episodes of depression.

**[0009]** In certain embodiments the present invention relates to method of predicting remission in depressed patients, wherein the antidepressant treatment is selected from the following classes selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), norepinephrine reuptake inhibitor (NRI), noradrenergic and specific serotonergic antidepressants (NaSSA), norepinephrine-dopamine disinhibitor (NDDI) or tricyclic antidepressant.

**[0010]** Antidepressants are drugs used for the treatment of clinical depression and other conditions.

**[0011]** Antidepressants for which the prediction of remission of the present invention provide results include antidepressants such as citalopram, escitalopram, paroxetine, fluoxetine, duloxetine, milnacipran, venlafaxine, atomoxetine, reboxetine, viloxazine, mianserin, mirtazapine, agomelatine.

**[0012]** In preferred embodiments the present invention relates to method of predicting remission based on activation of CMR at baseline to identify patients achieving remission after agomelatine treatment. Agomelatine or

N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, has the double characteristic of being, on the one hand, an agonist of receptors of the melatonergic system and, on the other hand, an antagonist of the 5-HT<sub>2C</sub> receptor.

**[0013]** The invention provides method of remission prediction, wherein the activated cortical midline regions are dorsomedial prefrontal cortex (dmPFC) and precuneus during self-referential processing. The present invention identifies brain regions, specifically dorsomedial prefrontal cortex and precuneus in cortical midline regions, whose activity during self-referential processing predict long-term remission among patients in depression treated with antidepressants.

**[0014]** The precuneus or the quadrate lobule of Foville or Brodmann Area 23 (BA23) is a part of the superior parietal lobule forward of the occipital lobe. The dorsomedial prefrontal cortex or dmPFC or DMPFC, preferably dorsomedial prefrontal cortex BA10 (dmPFC10), has been shown to be involved in attending different states, all including a strong emotional component.

**[0015]** In some embodiments the invention provides method of predicting remission based on activation in cortical midline regions at baseline discriminating patients achieving remission after antidepressant treatment, wherein the patients are suffering from Major Depressive Episode (MDE) preferably Major Depressive Disorder (MDD) or Bipolar Disorders.

**[0016]** Pretreatment activation in the dmPFC (BA10, BA8) and the precuneus during self-referential processing distinguished future remitters from non-remitters. Activation in these three regions was lower in remitters than in non-remitters and remained stable after 6/7 weeks of treatment in both groups of patients. Moreover pretreatment activation of dmPFC10 and precuneus predicted clinical remission at 6 months with a perfect sensitivity (100%) and a good specificity (71.6%).

**[0017]** Therefore, the level of activation of CMR during self-referential processing serves as a marker for predicting remission in a patient as described in the present invention. The present invention relates to methods of remission prediction wherein the activation of cortical midline regions during self-referential processing is lower in remitter patients in comparison with non-remitter patients. The invention encompasses a method of prediction remission in depressed patient wherein the cut-off level of remitter patients is determined by the discrimination ability of mean blood oxygen level dependent (BOLD) signal in function of the receiver operating characteristic (ROC) curve.

**[0018]** Actually, we used receiver operating characteristic (ROC) curve analysis to assess the discrimination ability of mean BOLD signal region of interest (ROIs) activity resulting from the contrast estimate between self-referential and general condition processing at baseline (W0), using SPSS 15.0 software. Then, from the ROC curve, we determined a cut-off value that maximized percentage correct discrimination, from the Youden index, equal to the sensitivity + specificity - 1. As an example,

the optimal cut-off from the dmPFC10 activation (i.e. 7.1) led to 81.25% correct prediction of remission and from the precuneus activation (i.e. 6.5) led to 87.5% correct prediction (for both, sensitivity of 100% and specificity of 71.6%).

**[0019]** Precuneus and dmPFC10 activation during self-referential processing at baseline predicted clinical changes at 24 weeks. Using baseline activation of these two regions, we were able to predict with robust specificity and sensitivity the long-term clinical outcome of patients. Pattern of brain activity clearly differentiated remitters from non-remitters suggesting cross-scanner generalizability and validating the clinical utility of such assessment. Consistent with previous studies, our results emphasized the role of cortical midline structures or regions (CMS) (including the dmPFC and precuneus) in self-referential processing and depression. Increased self-focus and impaired functioning of the CMS are crucial in the development and course of MDD. The present study is consistent with the idea that cortical midline structures activity play a major role in treatment outcome of MDD and could inform the choice of this treatment.

**[0020]** The present invention provides method of prediction remission whereby the pre-treatment activation or activation at baseline is measured by functional magnetic resonance imagery (fMRI).

**[0021]** Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases. The primary form of fMRI uses the Blood-oxygen-level dependent (BOLD) contrast.

**[0022]** In other embodiment the prediction of remission is validated if the long-term remission is achieved after 24 months, 12 months or preferably 6 months antidepressant treatment.

**[0023]** The present invention concerns agomelatine for use in treating a patient in need thereof, wherein the patient is identified by the method of prediction long-term remission according to the invention.

**[0024]** In other embodiments the invention relates to the use of pre-treatment activation in CMR for predicting long-term remission in patients with depression after depressant treatment.

**[0025]** The present invention is illustrated by the following Figures and Examples, without being limited thereby :

Figure 1 : Study plan design

Figure 2 : A. Example of fMRI experimental design. B. Example of stimuli presentation. For each picture, subjects gave either a 'yes' or 'no' response for the self condition, a 'positive' or 'negative' response for the general condition or a 'indoor' or 'outdoor' re-

sponse for the 'control' condition by pushing a button with the right- or the left- hand thumb.

Figure 3 : Demographic and clinical characteristics of MDD patients and Healthy Volunteers at baseline

Figure 4 : Demographic and clinical characteristics at baseline of future remitted and non-remitted patients 6 months later on.

Figure 5 : A. Mean BOLD signal from the regions of interest (main effect of group, ANOVA 2) in future remitters and non-remitters (at W24), at W0 and W7: dmPFC10 (MNI coordinates, -4 56 12), dmPFC8 (-10 48 42), precuneus (-8 -62 20). The bars graphs plot the contrast estimates between self-referential and general conditions per group and scan time. B. Negative correlation between the percentage of decrease in HAM-D score between the time W0 and W24 and the mean BOLD signal from dmPFC10, dmPFC8 and precuneus in self versus general condition at baseline (W0).

Figure 6 : Receiver operating characteristic (ROC) curves for remission computed using mean signal regions of interest (main effect of group, ANOVA 2) at baseline (W0).

### **Example : Identification of biomarkers to predict remission in depression**

#### **Subjects**

**[0026]** Twenty-five female outpatients meeting the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV, American Psychiatric Association) criteria for MDD with the Mini International Neuropsychiatric Interview were recruited between October 2008 and June 2011 by psychiatrists (seven centres located in Paris area, France). Current depressive episode had to be of moderate or severe intensity: 17-item Hamilton Depression Rating Scale (HAM-D; 10) total score  $\geq 22$  and Clinical Global Impression (CGI; 11) severity score  $\geq 4$ . Patients had to be free of psychotropic medication for a minimum of two weeks (washout period defined according to the medication) before inclusion. Patients with comorbid psychiatric conditions were excluded.

**[0027]** Before each fMRI scanning, a drug screening (for cannabinoids, opiates, amphetamines, metamphetamines, cocaine, and benzodiazepines), and alcohol breath were performed and subjects were excluded from analyses if positive. Four patients were excluded for positive screening for benzodiazepines before performing the third fMRI scan and two patients did not perform the third scan leading to a final sample of 19 MDD patients. They were compared to 14 healthy control subjects. Healthy volunteers were in good health as assessed by a complete medical questionnaire including medical his-

tory, a physical examination, and a psychiatric interview. They were not selected if there was any previous or ongoing chronic or recurrent disease of the central nervous system or psychiatric disorder (documented by the Mini International Neuropsychiatric Interview) or a family history of bipolar disorder or recurrent depression. None of the healthy volunteers used drugs acting on central nervous system.

#### **10 Study design and drug treatment**

**[0028]** Each patient was scanned on three occasions, before beginning the treatment (W0), after one week (W1) and seven weeks of treatment (W7). The controls were scanned on two occasions, at W0 and after one week (W1).

**[0029]** The study comprised two periods of treatment, one double-blind, placebo-controlled period of one week, with two parallel groups of MDD patients having taken either 1 tablet of agomelatine 25 mg (AGO) or one tablet of placebo (PBO), orally per day at around 8 p.m, during seven days in double-blind condition), followed by a period with agomelatine 25 mg until 24 weeks (W24).

**[0030]** All controls took one tablet of placebo orally per day at around 8 p.m., during seven days, in single-blind condition. (Figure 1)

#### **Clinical assessment**

**[0031]** Depression severity was assessed by the 17-item HAM-D scale and CGI severity and clinical improvement sub-scores before each fMRI scan (W0, W7) and after 24 weeks of treatments (W24) in MDD patients.

#### **35 Experimental design**

**[0032]** A total of 432 black and white pictures were taken from either the International Affective Picture System (IAPS) or the Empathy Picture System (EPS). 36 positive images, 36 negative images and 36 neutral images were used during each fMRI scanning and 36 used during practice sessions before fMRI scanning (12 per valence). So, each picture was seen only once by subjects during the fMRI scans.

**[0033]** The task comprised three judgment conditions: self, general and a control condition. In both self and general conditions, the subjects were presented with an equal number of positive and negative pictures. In the control condition, subjects were presented with neutral pictures. In the self condition, the subject judged if the picture was self-related or not. In the general condition, the subject judged if the picture was positive or negative. In the control condition, the subject had to state if the picture represented an outdoor or indoor scene (Figure 2).

### Clinical and behavioural data analysis

**[0034]** The analysis of clinical scales and task performance was conducted using the Statsoft Statistica version 10 ([www.statsoft.fr](http://www.statsoft.fr)) statistical package. Differences in demographic data (age, education) between both groups (patients and healthy subjects) were analysed with a two-sample Student t-test. Differences of ratings in HAM-D-17 scores between W0 and W7 (19 MDD patients), and between W7 and W24 (16 MDD patients) were compared using a paired-t test.

**[0035]** Differences in clinical characteristics between the two sub-groups of MDD patients (remitted and non-remitted at 24 weeks) before any treatment were compared using the parametric Student t-test or, when the population was not normally distributed (defined by the Kolmogorov-Smirnov test), the non-parametric test Mann-Whitney U-test for age, duration of disease, of current episode, number of previous depressive episodes and HAM-D-17 score, and using the chi-square test for DSM-IV classification.

**[0036]** Difference in task performance (accuracy score and reaction time during self, general and control conditions) were compared using an analysis of variance with a between-group factor (MDD patients, healthy subjects), and 3 within-group factors: condition factor (self/general/control), valence factor (positive/negative), scan time factor (W0/W7 for patients and W0/W1 for controls).

**[0037]** The threshold for statistical significance was fixed at  $p < 0.05$  (2-tailed).

### fMRI data preprocessing

**[0038]** Data were processed using the SPM5 software (<http://www.fil.ion.ucl.ac.uk/spm/software/spm5>). A standard data preprocessing was performed: slice timing, movement correction, co-registration with the T1-weighted image and normalization into a standardized MNI (Montreal Neurological Institute) coordinate system space using the transformations computed during the segmentation of the T1-weighted image, and finally spatial smoothing with an isotropic kernel of 8 mm full-width at half-maximum. An individual statistical parametric map was computed for each subject using the general linear model. Each condition was modelled using an event-related approach and convolved with the canonical hemodynamic response function (HRF) to create regressors of interest (self, general and control). A high-pass filter (cut-off of 128 seconds) was applied and motion realignment parameters included as regressors of non-interest. The following fist-level individual t-contrast images were obtained for the HRF estimates: "self versus general", "self versus control" and "general versus control" condition.

**[0039]** Because we did not observe any significant interaction between condition, valence and group at the first and second sessions ( $p < 0.005$ ) we did not take into

account emotional valence.

### Associations between pre-treatment brain activation at W0 and clinical change at W24

**[0040]** First we used HAM-D (i.e. the independent variable) as a categorical variable, to split the MDD sample in two groups according to a HAM-D score cut-off of 7 after 24 weeks of treatment (remitters  $\leq 7$ , non-remitters  $> 7$ ). Subsequently, we performed an ANOVA on "self versus general" contrast images (i.e. the dependent variable) with a between-group factor (remitters versus non-remitters) and a within-group scan time factor (W0 versus W7) (significant threshold  $p < 0.001$  uncorrected, size of cluster  $\geq 10$  voxels).

**[0041]** Second, we focused the analysis on the brain regions functionally defined on the basis of this ANOVA. The resulting peak coordinates were used as centers of 5-mm radius spheres and the mean signal was extracted from the ROIs at W0 using Marsbar software (<http://marsbar.sourceforge.net>). We used percentage of decrease in HAMD score between the time W0 and W24 as a continuous variable, computing Pearson's correlation coefficients with the mean signal ROIs (using the Statsoft Statistica version 10 statistical package).

**[0042]** Finally, to predict remission at 24 weeks, we used receiver operating characteristic (ROC) curve analysis to assess the discrimination ability of mean signal ROIs activity during self-referential processing at baseline (W0), using SPSS 15.0 software. Then, from the ROC curve, we determined a cut-off value that maximized percentage correct discrimination, from the Youden index, equal to the sensitivity + specificity - 1 (15).

### Demographic data

**[0043]** Figure 3 summarizes demographic and clinical characteristics of patients and controls. No significant difference was found between the two groups for age or education level.

### Clinical effects

**[0044]** No clinical difference in HAM-D scores was found before treatment between patients receiving Agomelatine for 6 or 7 weeks (PBO/AGO,  $n=10$  patients, HAM-D= $24.9 \pm 2.8$ ; AGO/AGO,  $n=9$  patients, HAM-D= $25.2 \pm 3.6$ ;  $p=0.4$ ).

**[0045]** The mean score of HAM-D decreased from W0 to W7 ( $25.1 \pm 3.1$  versus  $13.4 \pm 5.0$ ;  $t(18)=11.8$ ,  $p < 0.001$ ) and from W7 to W24 ( $8.8 \pm 6.3$ ;  $t(15)=2.8$ ,  $p=0.014$ ;  $n=16$  patients). At W7, ten patients (62,5%) were responders (score reduction  $\geq 50\%$ ), seven patients were partially responders (score reduction between 30 and 50%) and two patients were non-responders (score reduction  $< 30\%$ ).

**[0046]** Regarding CGI scores, the severity of illness at W0 decreased from "markedly" (mean= $4.9 \pm 0.5$ ) to "mildly"/"moderately" ( $3.4 \pm 1.1$ ) at W7 and to "borderline

mentally" ( $2.2 \pm 1.2$ ) at W24. Patients were "minimally" to "much" improved at W7 (mean= $2.4 \pm 0.8$ ) and "much" to "very much" improved at W24 ( $1.6 \pm 0.9$ ) (Figure 3).

**[0047]** Among the 16 patients included in the analyses of prediction, after 24 weeks of treatment we were able to distinguish nine remitters (56.2%) from seven non-remitters. At W0, future remitters and non-remitters did not differ for age, duration of disease, number of depressive episodes and severity of illness according to HAM-D score. The duration of the current episode was longer in non-remitters patients ( $7.9 \pm 4.9$  months) as compared to remitters ( $3.1 \pm 2.3$  months;  $U=11$ ,  $p=0.03$ ). According to the DSM-IV, there were more severe major depressive episodes in non-remitters compared to remitters patients ( $\chi^2=5.7$ ,  $p=0.02$ ) (Figure 4).

#### **fMRI results : Associations between pre-treatment brain activation and clinical change at 24 weeks**

**[0048]** Comparing remitters ( $n=9$ ) and non-remitters ( $n=7$ ), we observed a significant main effect of group in the dorsomedial prefrontal cortex BA10 (dmPFC10) (MNI coordinates: -4, 56, 12;  $F[1,28]=18.4$ ; small volume correction [SVC] 5mm-radius,  $t[28]=4.29$ ,  $p=0.002$ , 31 voxels), the dorsomedial prefrontal cortex BA8 (dmPFC8) (MNI coordinates: -10, 48, 42;  $F[1,28]=24.6$ ; SVC 5mm-radius,  $t[28]=4.96$ ,  $p=0.001$ , 49 voxels) and the precuneus BA 23 (MNI coordinates: -8, -62, 20;  $F[1,28]=19.6$ ; SVC 5mm-radius,  $t[28]=4.42$ ,  $p=0.002$ , 31 voxels). There was no effect of scan time or group  $\times$  scan time interaction suggesting that activation in these brain regions remained stable between W0 and W7.

**[0049]** The main effect of group was explained by a reduced activation in these three regions at baseline in future remitters compared to future non-remitters at both W0 and W7 (Figure 5A).

**[0050]** We tested the relationship of baseline activation in the dmPFC8, dmPFC10 and precuneus with clinical changes. There was a significant negative correlation between the percentage of decrease in HAM-D score from W0 to W24 and the activation at W0 in the dmPFC10 ( $r=-0.50$ ,  $t(14)=-2.19$ ,  $p=0.046$ ), the dmPFC8 ( $r=-0.58$ ,  $t(14)=-2.69$ ,  $p=0.018$ ) and a trend toward a significant negative correlation with the precuneus activation ( $r=-0.46$ ,  $t(14)=-1.95$ ,  $p=0.071$ ). Consistent with the categorical analysis comparing remitters and non-remitters, the less these three cortical midline regions were activated at baseline during self-referential processing, the better the improvement of clinical symptoms after 24 weeks of treatment by Agomelatine (Figure 5B).

#### **ROC (Receiver Operating Characteristic) analyses and prediction of remission at 24 weeks**

**[0051]** We took advantage of the individual variability of long-term clinical outcome in order to evaluate the accuracy of brain activation in dmPFC10, dmPFC8 and precuneus as predictors of remission at 24 weeks. The ROC

curves yielded a significant area under the curve (AUC) for the dmPFC10 (AUC=0.905,  $p=0.007$ ), the precuneus (AUC=0.921,  $p=0.005$ ), and a tendency for the dmPFC8 (AUC=0.762,  $p=0.081$ ) reflecting a good discrimination between future remitters and non-remitters from the activation of dmPFC10 and precuneus at baseline. The optimal cut-off led to 81.25% correct prediction of remission from the dmPFC10 activation and 87.5% correct prediction from the precuneus activation (for both, sensitivity of 100% and specificity of 71.6%) (Figure 6). Remitters were characterized by lower pre-treatment activation of dmPFC10 and precuneus during self-referential processing whereas higher activation of dmPFC10 and precuneus was associated with poor prognosis at 24 weeks.

#### **Claims**

1. Method of predicting remission in patients with depression wherein a level of activation at baseline in cortical midline regions (CMR) identify patients achieving remission after antidepressant treatment.
2. Method of claim 1, wherein the antidepressant treatment is selected from the antidepressant classes consisting in : selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), norepinephrine reuptake inhibitor (NRI), noradrenergic and specific serotonergic antidepressants (NaSSA), norepinephrine-dopamine disinhibitor (NDDI) or tricyclic antidepressant.
3. Method of claim 2, wherein the antidepressant is selected from the group consisting in : citalopram, escitalopram, paroxetine, fluoxetine, duloxetine, milnacipran, venlafaxine, atomoxetine, reboxetine, viloxazine, mianserin, mirtazapine, agomelatine.
4. Method of claim 3, wherein the antidepressant is agomelatine.
5. Method of claim 1, wherein the cortical midline regions are dorsomedial prefrontal cortex (dmPFC) and precuneus.
6. Method of claim 1, wherein the long-term remission is predicted in patients suffering from Major Depressive Episode (MDE) comprising Major Depressive Disorder (MDD) and Bipolar Disorders.
7. Method of claim 1, wherein the activation of cortical midline regions during self-referential processing is lower in remitter patients in comparison with non-remitter patients.
8. Method of claim 1, wherein the patients achieving remission after antidepressant treatment are under

the cut-off level determined by the discrimination ability of mean blood oxygen level dependent (BOLD) signal in function of the receiver operating characteristic (ROC) curve

5

9. Method of claim 1, wherein the pre-treatment activation is measured by functional magnetic resonance imagery (fMRI).
10. Method of claim 1, wherein the remission is achieved after 6 months antidepressant treatment.
11. agomelatine for use in treating a patient in need thereof, wherein the patient is identified by the method of prediction long-term remission of claims 1 to 10.
12. Use of pre-treatment activation in CMR for predicting long-term remission in patients with depression after depressant treatment.

20

25

30

35

40

45

50

55




Figure 1 : Study plan design




Figure 2 : fMRI experimental design

Characteristics	MDD patients (n=19)		HV (n=14)	
Age (years, mean±SD)	41.6	(±7.6)	41.6	(±7.4)
Min-max	27-52		26-53	
Right handed/left handed (n/n)	19/0		13/1	
Education (years, mean±SD)	13.6	(±1.8)	13.0	(±2.3)
DSM IV classification:				
- Recurrent episode (n)	18		-	
- Severity Moderate (n)	6		-	
Severe without psychotic feature (n)	13		-	
- Melancholic features (n)	15		-	
Duration of the disease (years, mean±SD)	14.1	(± 9.0)	-	
Current episode duration (months, mean±SD)	4.8	(± 4.0)	-	
Number of previous depressive episodes (including the current one) (mean±SD)	2.7	(± 1.3)	-	
HAM-D-17 score (mean±SD):				
W0	25.1	(± 3.1)	-	
W7	13.4	(± 5.0)	-	
*W24	8.8	(± 6.3)	-	
CGI sub-scores:				
severity of illness score (mean±SD) W0	4.9	(± 0.5)	-	
W7	3.4	(± 1.1)	-	
*W24	2.2	(± 1.2)	-	
global improvement score (mean±SD) W7	2.4	(± 0.8)	-	
*W24	1.6	(± 0.9)	-	

MDD=Major Depressive Disorder ; HV= Healthy Volunteers; SD=Standard Deviation; n=number of subjects

\*n=16

Figure 3 : Demographic and clinical characteristics of MDD patients and Healthy Volunteers at baseline

Characteristics	Remitted patients group (n=9)	Non-remitted patients group (n=7)
Age (years, mean±SD)	39.2 (±8.0)	44 (±7)
DSM IV classification:		
- Recurrent episode (n)	8	7
- Severity <sup>a</sup> Moderate (n)	5	0
Severe without psychotic feature (n)	4	7
- Melancholic features (n)	9	6
Duration of the disease (years, mean±SD)	10.7 (±5.1)	19.4 (±12.1)
Current episode duration <sup>b</sup> (months, mean±SD)	3.1 (±2.3)	7.9 (± 4.9)
Number of previous depressive episodes (including the current one) (mean±SD)	2.7 (±1.4)	2.7 (± 1.5)
HAMD-D-17 score at baseline (mean±SD)	24 (±2.3)	25.6 (± 3.6)

SD=Standard deviation; n=number of subjects

<sup>a</sup> p for difference between remitted and non-remitted patients =0.02

<sup>b</sup> p for difference between remitted and non-remitted patients =0.03

Figure 4 : Demographic and clinical characteristics at baseline of future remitted and non-remitted patients 6 months later on.




Figure 5 : A. Mean BOLD signal from the regions of interest

B. Negative correlation between the percentage of decrease in HAM-D score and mean BOLD signal from ROIs




Figure 6 : Receiver operating characteristic curves for remission



EUROPEAN SEARCH REPORT

Application Number  
EP 13 29 0238

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	EP 1 714 647 A1 (SERVIER LAB [FR]) 25 October 2006 (2006-10-25) * abstract * * paragraph [0001] * * claims 1-2 *	1-12	INV. A61B5/00  ADD. A61B5/055
X	EP 1 762 237 A1 (SERVIER LAB [FR]) 14 March 2007 (2007-03-14) * abstract * * paragraph [0001] * * claim 1 *	1-12	
X	K. E. DAVIES, I.V. LINNIK, S. MCKIE, J.A. STARK, S. LUCKMAN, L. SEQUIN, E. MOCAER, M. MILLAN, B. DEAKIN, AND S. R. WILLIAMS: "Effect of the Novel Anti-Depressant Agomelatine Determined by Pharmacological MRI in the Rat", INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE - PROCEEDING ISMRM - ESMRMB JOINT ANNUAL MEETING STOCKHOLM, 1-7 MAY 2010, 7 May 2010 (2010-05-07), XP040612471, * the whole document *	1-12	TECHNICAL FIELDS SEARCHED (IPC)  A61B
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of the search 7 January 2014	Examiner Marteau, Frédéric
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 13 29 0238

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-01-2014

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 1714647	A1	25-10-2006	AP 2656 A	07-05-2013
			AR 057277 A1	28-11-2007
			AT 491443 T	15-01-2011
			AU 2006201655 A1	09-11-2006
			BR PI0601285 A	19-12-2006
			CA 2544136 A1	20-10-2006
			CN 1853619 A	01-11-2006
			CN 102038669 A	04-05-2011
			CR 9426 A	21-02-2008
			DK 1714647 T3	07-03-2011
			EA 200600600 A1	27-10-2006
			EP 1714647 A1	25-10-2006
			ES 2357901 T3	03-05-2011
			FR 2884714 A1	27-10-2006
			GT 200600141 A	22-11-2006
			HK 1093906 A1	21-04-2011
			HR P20110083 T1	31-03-2011
			IL 186373 A	28-06-2012
			JO 2666 B	17-06-2012
			JP 4580364 B2	10-11-2010
			JP 5341037 B2	13-11-2013
			JP 2006316056 A	24-11-2006
			JP 2010280699 A	16-12-2010
			KR 20060110803 A	25-10-2006
			KR 20080028389 A	31-03-2008
			MA 28266 A1	01-11-2006
			MY 143171 A	31-03-2011
			NZ 546630 A	28-09-2007
			PE 13372006 A1	27-01-2007
			PT 1714647 E	14-01-2011
			RS 51659 B	31-10-2011
			SG 126868 A1	29-11-2006
			SI 1714647 T1	31-03-2011
TW I318115 B	11-12-2009			
TW 200940049 A	01-10-2009			
US 2006240127 A1	26-10-2006			
UY 29470 A1	31-05-2006			
WO 2006111653 A1	26-10-2006			
ZA 200603160 A	27-06-2007			
-----				
EP 1762237	A1	14-03-2007	AR 056063 A1	19-09-2007
			AU 2006209372 A1	29-03-2007
			BR PI0603762 A	15-05-2007
			CA 2558762 A1	09-03-2007
			CN 1927193 A	14-03-2007
			EA 200601449 A1	27-04-2007

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 13 29 0238

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-01-2014

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 1762237 A1	14-03-2007
		EP 2295050 A1	16-03-2011
		FR 2890562 A1	16-03-2007
		GT 200600409 A	30-04-2007
		HK 1100481 A1	09-09-2011
		JP 2007077148 A	29-03-2007
		KR 20070029608 A	14-03-2007
		KR 20080103043 A	26-11-2008
		MA 28506 B1	03-04-2007
		NZ 549726 A	28-03-2008
		PE 03332007 A1	02-06-2007
		SG 146451 A1	30-10-2008
		TW 200800148 A	01-01-2008
		UA 81573 C2	10-01-2008
		US 2007060655 A1	15-03-2007
		UY 29777 A1	31-10-2006
		WO 2007028905 A1	15-03-2007
		ZA 200607531 A	28-05-2008
-----			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

专利名称(译)	用于预测抑郁症长期缓解的生物标志物		
公开(公告)号	<a href="#">EP2856934A1</a>	公开(公告)日	2015-04-08
申请号	EP2013290238	申请日	2013-10-04
[标]申请(专利权)人(译)	施维雅药厂		
申请(专利权)人(译)	LES LABORATOIRES施维雅		
当前申请(专利权)人(译)	LES LABORATOIRES施维雅		
[标]发明人	JABOURIAN MARITZA FOSSATI PHILIPPE DELAVEAU PAULINE		
发明人	JABOURIAN, MARITZA FOSSATI, PHILIPPE DELAVEAU, PAULINE		
IPC分类号	A61B5/00 A61B5/055		
CPC分类号	A61B5/4848 A61B5/055		
审查员(译)	frÉdÉric锤		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

预测抑郁症患者长期缓解的方法。用于预测抑郁症长期缓解的生物标志物。




Figure 1 : Study plan design